ROYALTY PHARMA

ROYALTY PHARMA

Royalty Pharma plc

Q1 2023 Financial Results

May 9, 2023

Forward Looking Statements & Non-GAAP Financial Information

This presentation has been prepared by Royalty Pharma plc (the "Company"), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither the delivery of this presentation at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof. This presentation contains statements that constitute "forward-looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "target," "forecast," "guidance," "goal," "predicts," "project," "potential," or "continue," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the Company. However, these forward-looking statements are not a guarantee of the Company's performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law. Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the Company believes its own internal research is reliable, such research has not been verified by any independent source. For further information, please see the Company's reports and documents filed with the U.S. Securities and Exchange Commission ("SEC") by visiting EDGAR on the SEC's website at www.sec.gov.

Also, the discussions during this conference call will include certain financial measures that were not prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). Additional information regarding non-GAAP financial measures can be found on slide 24 and in the Company's earnings release furnished with its Current Report on Form 8-K dated May 9, 2023, which are available on the Company's website. Any non-GAAP financial measures presented are not, and should not be viewed as, substitutes for financial measures required by GAAP, have no standardized meaning prescribed by GAAP and may not be comparable to the calculation of similar measures of other companies.

Agenda

Key Highlights	Pablo Legorreta	Founder & Chief Executive Officer
Portfolio Update	Marshall Urist	EVP, Head of Research & Investments
Financial Results	Terrance Coyne	EVP, Chief Financial Officer
Conclusion	Pablo Legorreta	Founder & Chief Executive Officer
Q&A	Pablo Legorreta Terrance Coyne Chris Hite Marshall Urist	Founder & Chief Executive Officer EVP, Chief Financial Officer EVP, Vice Chairman EVP, Head of Research & Investments

Key Highlights

Pablo Legorreta

Founder & Chief Executive Officer

ROYALTY PHARMA

Executing against our strategic objectives in Q1 2023

1 Financial performance

Adjusted Cash Receipts ("top-line")[1,2] +11%

Adjusted EBITDA[1,2] +11%

Adjusted Cash Flow[1,2] +49%

2 Capital allocation

Transactions announced YTD of up to $1.6bn[3] ($600m upfront)

Authorized $1bn multi-year share repurchase program

3 Positive portfolio progress

Positive Phase 3 results for Xtandi in nmCSPC[4]

U.S. FDA approvals granted for Zavzpret for migraine[5], Airsupra for asthma[6], Trodelvy for HR+/HER2- mBC[7]

4 Full-year guidance

Adjusted Cash Receipts[1] expected to be $2,850m to $2,950m excluding future investments[8]

~+4% to +9% underlying growth prior to Biohaven related payments[9] excluding future transactions

nmCSPC: non-metastatic castration-sensitive prostate cancer; FDA: Food and Drug Administration; HR+/HER2-: hormone receptor-positive, human epidermal growth factor receptor 2-negative, mBC: metastatic breast cancer.

1. See slide 24 for definitions and additional information. 2. Growth rates are prior to the $475 million Zavzpret accelerated milestone payments received in Q1 2023 and the $13 million Series A Biohaven Preferred Shares redemption payment received in Q1 2022. 3. Announced transaction amount includes potential milestone payments. 4. Pfizer and Astellas press release, March 17, 2023. 5. Pfizer press release, March 10, 2023. 6. AstraZeneca press release, January 11, 2023. 7. Gilead press release, February 3, 2023. 8. Adjusted Cash Receipts guidance excludes contribution from transactions announced subsequent to the date of this presentation. 9. Biohaven related payments include $475m in Adjusted Cash Receipts from the Zavzpret milestone payment in Q1 2023 and $458m in Adjusted Cash Receipts from Pfizer's accelerated Biohaven payment and $52m from the Series A Biohaven Preferred Shares redemption payments in full year 2022.

Double-digit growth in Q1 2023

Adjusted Cash Receipts[1]
($ in millions)

+87% reported Adjusted Cash Receipts[1] growth



Adjusted EBITDA[1]
($ in millions)

+88% reported Adjusted EBITDA[1] growth



Adjusted Cash Flow[1]
($ in millions)

+165% reported Adjusted Cash Flow[1] growth

$100m upfront and milestone development-stage payments[2]



Biohaven Series A fixed payment Zavzpret milestone payment

Estimated foreign exchange impact of ~-3% to -4%[3] to Q1 2023 Adjusted Cash Receipts[1]

ROYALTY PHARMA

ACR: Adjusted Cash Receipts
1. See slide 24 for definitions. Refer to Royalty Pharma's Current Report on Form 8-K dated May 9, 2023 for a GAAP to non-GAAP reconciliation. 2. Related to Cytokinetics in Q1 2022. 3. See slide 24 for additional discussion regarding the assumptions for estimated foreign exchange impacts.

Impressive track record of strong top-line[(1)] growth since IPO



1. Top line refers to Royalty Pharma's Adjusted Cash Receipts
2. See slide 24 for definitions. Refer to Royalty Pharma's Current Report on Form 8-K dated May 9, 2023 for a GAAP to non-GAAP reconciliation.
3. On pro forma basis. See slide 24 for definition and additional information.
4. Growth of 12% is prior to the $458m accelerated Biohaven redemption payment received in Q4 2022.
5. Growth of 11% is prior to the $475m Zavzpret milestone payment received in Q1 2023 and $13m in Series A fixed payment received in Q1 2022.

Existing portfolio powered ~11% growth despite LOEs and FX

Q1 2023 Adjusted Cash Receipts[1]



ACR: Adjusted Cash Receipts; FX: foreign exchange; LOE: loss of exclusivity

1. See slide 24 for definitions. 2. Includes $16 million (less $3 million distribution to non-controlling interests) quarterly redemption payment related to the Series A Biohaven Preferred Shares. 3. Primarily includes Januvia, Janumet and Other DPP-IVs. 4. Base business is defined as royalties in Royalty Pharma's portfolio as of December 31, 2022. 5. See slide 24 for additional discussion regarding the assumptions for estimated foreign exchange impacts.

Portfolio Update

Marshall Urist, MD, PhD

Executive Vice President
Head of Research & Investments

ROYALTY PHARMA

KarXT – exciting development-stage therapy for schizophrenia

- Acquired PureTech's royalty on Karuna's KarXT for schizophrenia
  - $100 million upfront payment
  - $400 million in potential regulatory and sales milestones
  - Entitled to 3% royalty on sales up to $2 billion annually, after which Royalty Pharma receives an approximate 1% royalty
- Early and sustained reduction of positive and negative symptoms of schizophrenia seen in Phase 3 studies[1]
  - Generally well-tolerated; may not be associated with common adverse events of current medications[2]
- Karuna plans to submit an NDA to the U.S. FDA in Q3 2023[3]

KarXT consensus sales projections[4]
($ in billions)



NDA: new drug application; FDA: Food and Drug Administration

1. KarXT demonstrated a statistically significant and clinically meaningful 9.6-point reduction in the Positive and Negative Syndrome Scale (PANSS) total score compared to placebo (-21.2 KarXT vs. -11.6 placebo, p<0.0001) at Week 5 (Cohen's d effect size of 0.61) in EMERGENT-2. KarXT demonstrated a statistically significant and clinically meaningful 8.4-point reduction in PANSS total score compared to placebo (-20.6 KarXT vs. -12.2 placebo; p<0.0001) at Week 5 (Cohen's d effect size of 0.60) in EMERGENT-3.
2. Measures of weight gain, somnolence, and extrapyramidal symptoms of KarXT were similar to placebo in the EMERGENT-2 and EMERGENT-3 clinical trials.
3. Karuna Q1 2023 earnings press release, May 4, 2023.
4. Visible Alpha as of April 2023. Represents unadjusted sales for KarXT.

Significant unmet need for new treatments in schizophrenia

Majority of patients discontinue or cycle therapy[1]

(Current pharmacological responses)



Invested in two exciting new mechanisms in development

	1 KarXT	2 MK-8189
Mechanism	M1/M4 muscarinic agonist	PDE10A inhibitor
Stage of development	Two positive Phase 3 trials	Phase 2b
Investment	$100m upfront; up to $400m in potential milestones	$50m upfront; option for up to $375m to co-fund Phase 3 following large Phase 2b
Marketer	Karuna	Merck

1. Karuna Phase 3 EMERGENT-3 topline data results presentation, March 2023.

Selected investment themes of interest



Therapeutic area agnostic investment approach follows best opportunities

HCM: hypertrophic cardiomyopathy; Lp(a): Lipoprotein(a)

Balanced royalty acquisition strategy

~$21 billion in cumulative capital deployed

($ in billions)



Annual capital deployment



Capital deployed balanced on average across approved and development stage therapies with some annual variability

Financial Results

Terrance Coyne

Executive Vice President
Chief Financial Officer

ROYALTY PHARMA

Strong growth in total royalty receipts in Q1 2023



CF: cystic fibrosis

1. Amounts may not add due to rounding.
2. Other is positively impacted by a $35m Airsupra payment in Q1 2023 and negatively impacted by a $16m quarterly redemption payment related to the Series A Biohaven Preferred Shares in Q1 2022.

Efficient model generates substantial cash flow to reinvest

$ in millions (except per share amount)	Q1 2023	YoY % change	% ACR	Comments
Royalty receipts	1,223	72%		
Distributions to legacy non-controlling interests- royalty receipts	-92	-14%		Decline primarily reflects end of Januvia, Janumet and other DPP-IV royalties
Adjusted Cash Receipts (non-GAAP)[1]	1,131	**87%**		**"Top-line"** (includes $475m Zavzpret milestone)
Payments for operating and professional costs	-87	78%	7.7%	
Adjusted EBITDA (non-GAAP)[1]	1,044	**88%**	**92.3%**	Adjusted EBITDA less net interest = **$977m to deploy**
Interest paid, net	-67			
Development-stage funding payments - ongoing	-1			
Other[2]	-3			
Adjusted Cash Flow (non-GAAP)[1]	973	**165%**	**86.1%**	**"Bottom-line"**
	$1.60/share[3]			

ACR: Adjusted Cash Receipts

1. Refer to slide 24 for definitions. Refer to Royalty Pharma's Current Report on Form 8-K dated May 9, 2023 for a GAAP to non-GAAP reconciliation.
2. Includes investments in equity method investees and contributions from legacy non-controlling interests- R&D.
3. Based on weighted-average diluted Class A ordinary shares outstanding of 607 million for the three months ended March 31, 2023.

Significant financial capacity for future royalty acquisitions

- $2.0bn of cash, cash equivalents and marketable securities as of March 31, 2023
- Capital deployed of $618m in Q1 2023
- $7.3bn of investment grade debt currently outstanding
  - Total leverage of 2.3x[1]
  - Net leverage of 1.7x[2]

Cash, cash equivalents & marketable securities

($ in millions)



1. Total leverage is calculated as Total debt divided by EBITDA (as defined in credit agreement); refer to Exhibit 10-2 of the RPRX IPO S-1 for compliance EBITDA calculation.
2. Net leverage is calculated as Total debt less cash and marketable securities divided by EBITDA (as defined in credit agreement); refer to Exhibit 10-2 of the RPRX S-1 for compliance EBITDA calculation.
3. Refer to slide 24 for definitions; refer to Royalty Pharma's Current Report on Form 8-K dated May 9, 2023 for a GAAP to non-GAAP reconciliation.
4. Acquisitions primarily relate to the Ionis transaction and acquisition of royalties on KarXT.
5. Reflects dividends on Class A ordinary shares and Class B ordinary shares.
6. Primarily includes contributions from non-controlling interests and other items.

Capital allocation strategy to drive shareholder value creation

$20 billion in projected 2022-2026 capacity to reinvest and return to shareholders

Royalty acquisitions

$10-$12bn 5-year target[1]

- Announced ~$5.0bn since 2022 (~$2.6bn deployed upfront)
- Robust and active transaction pipeline
- Largely self-funded over time via retained cash flow

Additional Capacity

Royalty investments prioritized

- >$4bn capacity with conservative leverage
- Committed to investment grade credit rating



Share repurchases

Up to $1bn (announced March 2023)

- Received shareholder approval at AGM in June 2022
- Authorization valid through June 2027

Dividends

~2.0% annual yield

- Current dividend of $0.20/quarter
- Commitment to the dividend

Capital allocation balances primary focus of acquiring royalties with returning capital to shareholders

AGM: Annual General Meeting

1. 5-year capital deployment target provided at May 2022 Investor Day.
2. Cumulative 5-year capacity includes cash generated from operations, future acquisitions and debt capacity. Figure provided at May 2022 Investor Day.

Full-year 2023 guidance[1,2]

	February 15, 2023[3]	May 9, 2023	Comments
Adjusted Cash Receipts (non-GAAP) excluding transactions announced subsequent to May 9, 2023[1,2]	**$2,375m - $2,475m**	**$2,850m - $2,950m[4]** (increased March 15)	• Strong portfolio performance, partially offset by Imbruvica weakness • $475m Zavzpret milestone payment in 2023 • Foreign exchange impact of ~-1% to -2%[5]
Operating & professional costs	**~8.0% - 9.0%** of ACR[1,2]	**~8.0% - 9.0%** of ACR[1,2]	• Unique business model provides margin protection despite inflationary environment
Interest paid	**~$170m**	**~$170m**	• Assumes no issuance of additional debt • *De minimis* interest paid expected in Q2 and Q4 2023 • Excludes interest received, which was $16m in Q1 2023

ACR: Adjusted Cash Receipts

1. See Slide 24 for definitions and for additional information regarding Royalty Pharma's 2023 full-year financial guidance. 2. This guidance is as of May 9, 2023 and assumes no major unforeseen adverse events and excludes any potential contribution from transactions announced subsequent to that date. Furthermore, Royalty Pharma may amend its guidance in the event it engages in new royalty transactions which have a material near-term financial impact on the Company. See the information on page 3, "Forward Looking Statements & Non-GAAP Financial Information," for factors that may impact the achievement of this guidance. 3. Provided during Royalty Pharma's fourth quarter 2022 earnings on February 15, 2023. 4. Royalty Pharma raised its 2023 Adjusted Cash Receipts guidance to be between $2,850m to $2,950m from between $2,375m to $2,475m on March 15, 2023, following receipt of the Zavzpret milestone payment. 5. See slide 24 for additional discussion regarding the assumptions for estimated foreign exchange impacts.

Underlying growth in 2023 driven by existing portfolio

Biohaven payment added $509m in ACR in 2022

($458m accelerated payment; $52m Series A fixed payment)
($ in millions)



Solid underlying ACR growth expected in 2023

($ in millions)



Guidance excludes future transactions which may increase Adjusted Cash Receipts(1) growth

ACR: Adjusted Cash Receipts; FX: foreign exchange

1. See slide 24 for definitions. 2. Biohaven payment includes $458m in Adjusted Cash Receipts from Pfizer's accelerated Biohaven payment and $52m in Adjusted Cash Receipts from the Series A Biohaven Preferred Shares redemption payments in 2022. 3. Primarily includes Januvia, Janumet and Lexiscan. 4. Base business is defined as royalties in Royalty Pharma's portfolio as of December 31, 2022. 5. See slide 24 for additional discussion regarding the assumptions for estimated foreign exchange impacts. 6. Royalty Pharma's 2023 Adjusted Cash Receipts guidance of $2,850m to $2,950m excludes transactions announced subsequent to the date of this earnings release.

Conclusion

Pablo Legorreta

Founder & Chief Executive Officer

ROYALTY PHARMA

A unique way to invest in biopharma

		ROYALTY PHARMA	Large biopharma[1]
Growth	2020-2030 top-line[2] CAGR	10% or more[2]	4%[3]
Scale	Number of blockbusters[4]	15	9
Cost of capital	Estimated WACC	Mid-single digits	Mid-single digits
Risk	Stage of development	Post proof-of-concept to approved	Pre-clinical to approved
Return	Historical return on investments[5]	Consistent low teens IRR	?
Income	Dividend yield	2%	3%
Ownership	Management % ownership of FDSO	16%[6]	<1%[6]

CAGR: compound annual growth rate; WACC: weighted average cost of capital; IRR: internal rate of return; FDSO: fully diluted shares outstanding

1. Consists of Eli Lilly, Johnson & Johnson, Merck, Pfizer, AbbVie, Bristol Myers Squibb, Gilead, Amgen, Biogen, Vertex, Regeneron, Roche, Novartis, GSK, Sanofi, Novo Nordisk and AstraZeneca.
2. Top-line refers to Royalty Pharma's Adjusted Cash Receipts and includes future investments. Royalty Pharma growth target provided at May 2022 Investor Day. See slide 24 for definitions.
3. Source: Visible Alpha.
4. Calculated based on 2022 end market sales and excludes products tied to recently expired royalties.
5. Historical return on investments for Royalty Pharma is from 2012 to Q1 2023; biopharma returns on investments in business development, M&A and R&D.
6. Represents Named Executive Officer (NEO) ownership reported by CapIQ for Large biopharma; Royalty Pharma NEO ownership as disclosed in 2022 proxy filing.

Footnotes

1) To aid in comparability, quarter-over-quarter growth in 2020 is calculated based on pro forma 2019 results, which adjusts certain cash flow line items as if Royalty Pharma's Reorganization Transactions (as described in the Company's final prospectus filed with the SEC on June 17, 2020 ("Prospectus")) and its initial public offering ("IPO") had taken place on January 1, 2019. The most significant difference between the pro forma and reported figures is the new non-controlling interest that resulted from the Reorganization Transactions. A new contractual non-controlling interest arose in the Reorganization Transactions that results in a higher distribution to non-controlling interests on a pro forma basis as compared to prior historical periods. Less material differences also arise in the Royalty Receipts line for other products as well as Payments for operating and professional costs, interest paid, net, and in the payments associated with our former interest rate swap contracts.

2) Adjusted Cash Receipts is a measure calculated with inputs directly from the statements of cash flows and includes (1) total royalty receipts: (i) Cash collections from royalty assets (financial assets and intangible assets), (ii) *Other royalty cash collections*, (iii) *Distributions from equity method investees*, plus (2) *Proceeds from available for sale debt securities*, less (1) *Distributions to legacy non-controlling interests - royalty receipts*, which represent contractual distributions of royalty receipts and proceeds from available for sale debt securities to the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust (RPSFT). See the Company's Annual Report on Form 10-K filed with the SEC on February 15, 2023 for additional discussion. See GAAP to Non-GAAP reconciliation in the Company's Current Report on Form 8-K dated May 9, 2023.

3) Adjusted EBITDA is important to lenders and is defined under the Credit Agreement as Adjusted Cash Receipts less payments for operating and professional costs. Operating and professional costs reflect *Payments for operating and professional costs* from the statements of cash flows. See GAAP to Non-GAAP reconciliation in the Company's Current Report on Form 8-K dated May 9, 2023. See the Company's Annual Report on Form 10-K filed with SEC on February 15, 2023 for additional discussion on defined term.

4) Adjusted Cash Flow is defined as Adjusted EBITDA less (1) *Development-stage funding payments - ongoing*, (2) *Development-stage funding payments - upfront and milestone*, (3) *Interest paid*, net of *Interest received*, (4) *Investments in equity method investees* and (5) Other (including *Derivative collateral posted*, net of *Derivative collateral received* and *Termination payments on derivative instruments*) plus (1) *Contributions from legacy non-controlling interests - R&D*, all directly reconcilable to the statements of cash flows. See GAAP to Non-GAAP reconciliation in the Company's Current Report on Form 8-K dated May 9, 2023.

5) Foreign exchange impact represents an estimate of the difference in results that are attributable to fluctuations in currency exchange rates based on certain assumptions of prevailing exchange rates for the related period, contractual terms, geographies from which our royalties are derived, timing of payments and other factors. The marketers paying us royalties may not provide or may not be required to provide the breakdown of product sales by geography. Actual foreign exchange impact may be different than our estimates.

Financial Guidance footnote

6) Royalty Pharma has not reconciled its non-GAAP 2023 guidance to the most directly comparable GAAP measure, net cash provided by operating activities, at this time due to the inherent difficulty in accurately forecasting and quantifying certain amounts that are necessary for such reconciliation, including, primarily, payments for operating and professional costs, distributions from equity method investees, and interest received. The Company is not able to forecast on a GAAP basis with reasonable certainty all adjustments needed in order to project net cash provided by operating activities on a GAAP basis at this time.

Appendix

ROYALTY PHARMA

Distributions to legacy non-controlling interests (NCI)

- Royalty Pharma includes several non-controlling interests in our financial statements.
- The largest of these impacting the non-GAAP financial measures is an ~17.6% interest in substantially all of Royalty Pharma's pre-IPO investments held by some legacy investors. These legacy investors do not participate in acquisitions of royalties since our June 2020 IPO.
- The interest of these legacy investors will exist through the life of the pre-IPO investments, but is expected to decline over time as a percentage of total royalty receipts.
- Q1 2023 distributions to NCI as a percentage of royalty receipts declined to 7.5% versus 15.0% in Q1 2022.
- Q1 2023 distributions to NCI would have been 12.3% of royalty receipts prior to the Zavzpret milestone payment.

Products	Q1 2023 NCI as a % of royalty receipts
Zavzpret milestone	0.0%
Cystic fibrosis franchise[1]	8.8%
Tysabri	17.6%
Imbruvica	17.6%
Promacta	17.6%
Trelegy	0.0%
Xtandi	17.6%
Tremfya	0.0%
Evrysdi	0.0%
Cabometyx/Cometriq	0.0%
Farxiga/Onglyza	17.6%
Trodelvy	17.6%
Erleada	17.6%
Orladeyo	0.0%
Crysvita	17.6%
Nurtec ODT[1]	14.8%
Emgality	17.6%
Prevymis	0.0%
Other products (blended)	18.2%
Total products (blended)	**7.5%**

1. The cystic fibrosis franchise and Nurtec ODT NCI % figures represent a blend across multiple royalty interests.

Multiple important milestones expected in 2023

Select year-to-date and expected upcoming events



Clinical	Xtandi Phase 3 results for nmCSPC (EMBARK)[1]
	Cabometyx, Tecentriq Phase 3 results for RCC during or following ICI (CONTACT-03)[2]
	Tremfya Phase 3 results for ulcerative colitis[3]
	Tremfya Phase 3 results for Crohn's disease[4]
	Cabometyx, Opdivo, Yervoy Phase 3 OS results for 1L renal cell carcinoma (COSMIC 313)[5]
	Seltorexant Phase 3 results for major depressive disorder with insomnia symptoms[6]
	Cabometyx, Tecentriq Phase 3 results for mCRPC (CONTACT-02)[5]
	Aficamten Phase 3 results for obstructive hypertrophic cardiomyopathy (SEQUOIA-HCM)[7]
	Pelabresib, Jakafi Phase 3 results for myelofibrosis (MANIFEST-2)[8]
Regulatory	Airsupra FDA decision in asthma[9]
	Trodelvy FDA decision in 3L+ HR+/HER2- metastatic breast cancer[10]
	Zavzpret (intranasal zavegepant) FDA decision in migraine[11]
	Omecamtiv mecarbil FDA decision in heart failure[12]
	Trikafta FDA decision in cystic fibrosis patients ages 2 to 5[13]
	KarXT regulatory FDA filing[14]

nmCSPC: non-metastatic castration sensitive prostate cancer; RCC: renal cell carcinoma; ICI: immune checkpoint inhibitor; OS: overall survival; mCRPC: metastatic castration-resistant prostate cancer; FDA: Food & Drug Administration

1. Astellas press release, March 17, 2023. 2. Exelixis press release, March 2, 2023. 3. Digestive Disease Week abstract presentation 769, May 9, 2023. 4. Johnson & Johnson Pharmaceuticals Pipeline – Key Events 2023, April 18, 2023. 5. Exelixis Q4 2022 earnings presentation, February 7, 2023. 6. www.clinicaltrials.gov. 7. Cytokinetics Q1 2023 earnings release, May 4, 2023. 8. MorphoSys press release, April 4, 2023. 9. AstraZeneca press release, January 11, 2023. 10. Gilead press release, February 3, 2023. 11. Pfizer press release, March 10, 2023. 12. Cytokinetics press release, February 28, 2023. 13. Vertex press release, April 26, 2023. 14. Karuna Q1 2023 earnings press release, May 4, 2023.

Potential royalties on ~35 projects in late-stage development



HNSCC: head and neck squamous cell carcinoma; AD: Alzheimer's disease; mUC: metastatic urothelial carcinoma; NSCLC: non-small-cell lung carcinoma; oHCM: obstructive hypertrophic cardiomyopathy; mTNBC: metastatic triple negative breast cancer; TNBC: triple negative breast cancer; nOH: neurogenic orthostatic hypotension; MSA: multiple system atrophy; RCC: renal cell carcinoma; mCRPC: metastatic castration-resistant prostate cancer; MDD: major depressive disorder; nmCSPC: non-metastatic castration sensitive prostate cancer; PsA: Psoriatic Arthritis

1. EVOKE-02. 2. High risk localized advanced prostate cancer prior to radical prostatectomy. 3. High risk localized advanced prostate cancer receiving primary radiation therapy. 4. EVOKE-03.